Association of COVID-19 Vaccines ChAdOx1-S and BNT162b2 with Circulating Levels of Coagulation Factors and Antithrombin
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Participants
2.2. Measurement of Plasma SARS-CoV-2-Specific Antibodies via Enzyme-Linked Immunosorbent Assays
2.3. Measurement of Plasma Coagulation Factors and Antithrombin via Enzyme-Linked Immunosorbent Assays
2.4. Statistical Analysis
3. Results and Discussion
4. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- World Health Organization COVID-19 Update. Available online: https://covid19.who.int/ (accessed on 1 April 2022).
- Zhou, P.; Yang, X.-L.; Wang, X.-G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.-R.; Zhu, Y.; Li, B.; Huang, C.-L.; et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020, 579, 270–273. [Google Scholar]
- Wu, F.; Zhao, S.; Yu, B.; Chen, Y.-M.; Wang, W.; Song, Z.-G.; Hu, Y.; Tao, Z.-W.; Tian, J.-H.; Pei, Y.-Y.; et al. A new coronavirus associated with human respiratory disease in China. Nature 2020, 579, 265–269. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sharma, O.; Sultan, A.A.; Ding, H.; Triggle, C.R. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front. Immunol. 2020, 11, 585354. [Google Scholar] [CrossRef] [PubMed]
- Chung, Y.H.; Beiss, V.; Fiering, S.N.; Steinmetz, N.F. COVID-19 Vaccine Frontrunners and Their Nanotechnology Design. ACS Nano 2020, 14, 12522–12537. [Google Scholar] [CrossRef]
- Lee, P.; Kim, C.-U.; Seo, S.H.; Kim, D.-J. Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages. Immune Netw. 2021, 21, e4. [Google Scholar] [CrossRef] [PubMed]
- Callaway, E. The race for coronavirus vaccines: A graphical guide. Nature 2020, 580, 576–577. [Google Scholar] [CrossRef]
- Liu, C.; Zhou, Q.; Li, Y.; Garner, L.V.; Watkins, S.P.; Carter, L.J.; Smoot, J.; Gregg, A.C.; Daniels, A.D.; Jervey, S.; et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent. Sci. 2020, 6, 315–331. [Google Scholar] [CrossRef] [PubMed]
- Bosch, B.J.; van der Zee, R.; de Haan, C.A.; Rottier, P.J.M. The coronavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex. J. Virol. 2003, 77, 8801–8811. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kaur, S.P.; Gupta, V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020, 288, 198114. [Google Scholar] [CrossRef]
- Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [Google Scholar] [CrossRef]
- Folegatti, P.M.; Ewer, K.J.; Aley, P.K.; Angus, B.; Becker, S.; Belij-Rammerstorfer, S.; Bellamy, D.; Bibi, S.; Bittaye, M.; Clutterbuck, E.A.; et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020, 396, 467–478. [Google Scholar] [CrossRef]
- Abu-Farha, M.; Al-Sabah, S.; Hammad, M.M.; Hebbar, P.; Channanath, A.M.; John, S.E.; Taher, I.; Almaeen, A.; Ghazy, A.; Mohammad, A.; et al. Prognostic Genetic Markers for Thrombosis in COVID-19 Patients: A Focused Analysis on D-Dimer, Homocysteine and Thromboembolism. Front. Pharmacol. 2020, 11, 587451. [Google Scholar] [CrossRef] [PubMed]
- Tang, N.; Li, D.; Wang, X.; Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020, 18, 844–847. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Panigada, M.; Bottino, N.; Tagliabue, P.; Grasselli, G.; Novembrino, C.; Chantarangkul, V.; Pesenti, A.; Peyvandi, F.; Tripodi, A. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J. Thromb. Haemost. 2020, 18, 1738–1742. [Google Scholar] [CrossRef] [PubMed]
- Ranucci, M.; Ballotta, A.; Di Dedda, U.; Baryshnikova, E.; Poli, M.D.; Resta, M.; Falco, M.; Albano, G.; Menicanti, L. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J. Thromb. Haemost. 2020, 18, 1747–1751. [Google Scholar] [CrossRef] [PubMed]
- Schultz, N.H.; Sørvoll, I.H.; Michelsen, A.E.; Munthe, L.A.; Lund-Johansen, F.; Ahlen, M.T.; Wiedmann, M.; Aamodt, A.-H.; Skattør, T.H.; Tjønnfjord, G.E.; et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N. Engl. J. Med. 2021, 384, 2124–2130. [Google Scholar] [CrossRef]
- Dias, L.; Soares-Dos-Reis, R.; Meira, J.; Ferrão, D.; Soares, P.R.; Pastor, A.; Gama, G.; Fonseca, L.; Fagundes, V.; Carvalho, M. Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine. J. Stroke Cerebrovasc. Dis. 2021, 30, 105906. [Google Scholar] [CrossRef]
- Cines, D.B.; Bussel, J.B. SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia. N. Engl. J. Med. 2021, 384, 2254–2256. [Google Scholar] [CrossRef]
- Vojacek, J.F. Should We Replace the Terms Intrinsic and Extrinsic Coagulation Pathways With Tissue Factor Pathway? Clin. Appl. Thromb. Hemost. 2017, 23, 922–927. [Google Scholar] [CrossRef] [Green Version]
- Chaudhry, R.; Usama, S.M.; Babiker, H.M. Physiology, Coagulation Pathways. In StatPearls [internet]. StatPearls Publishing: Treasure Island, FL, USA, 2022. [Google Scholar]
- Meijers, J.C.; Tekelenburg, W.L.; Bouma, B.N.; Bertina, R.M.; Rosendaal, F.R. High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis. N. Engl. J. Med. 2000, 342, 696–701. [Google Scholar] [CrossRef]
- Johansson, K.; Jansson, J.-H.; Johansson, L.; Bylesjö, I.; Nilsson, T.K.; Eliasson, M.; Söderberg, S.; Lind, M. Factor XII as a Risk Marker for Hemorrhagic Stroke: A Prospective Cohort Study. Cerebrovasc. Dis. Extra 2017, 7, 84–94. [Google Scholar] [CrossRef] [PubMed]
- Shemirani, A.H.; Szomják, E.; Csiki, Z.; Katona; Bereczky, Z.; Muszbek, L. Elevated factor XIII level and the risk of peripheral artery disease. Haematologica 2008, 93, 1430–1432. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Smolkin, M.B.; Perrotta, P.L. Chapter 18-Molecular Diagnostics for Coagulopathies. In Diagnostic Molecular Pathology; Coleman, W.B., Tsongalis, G.J., Eds.; Academic Press: Cambridge, MA, USA, 2017; pp. 221–233. [Google Scholar]
- Flood, V.H.; Scott, J.P. 38-Bleeding and Thrombosis. In Nelson Pediatric Symptom-Based Diagnosis; Kliegman, R.M., Toth, H., Bordini, B.J., Basel, D., Eds.; Elsevier: Amsterdam, The Netherlands, 2018; pp. 682–700.e1. [Google Scholar]
- Moosavi, M.; Wooten, M.; Goodman, A.; Nahab, F.B.; Duncan, A.; Maier, C.; Guarner, J. Retrospective Analyses Associate Hemostasis Activation Biomarkers With Poor Outcomes in Patients With COVID-19. Am. J. Clin. Pathol. 2021, 155, 498–505. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hasan, A.; Arefanian, H.; Channanath, A.M.; AlKhairi, I.; Cherian, P.; Devarajan, S.; Thanaraj, T.A.; Abu-Farha, M.; Abubaker, J.; Al-Mulla, F. Association of COVID-19 Vaccines ChAdOx1-S and BNT162b2 with Circulating Levels of Coagulation Factors and Antithrombin. Vaccines 2022, 10, 1226. https://doi.org/10.3390/vaccines10081226
Hasan A, Arefanian H, Channanath AM, AlKhairi I, Cherian P, Devarajan S, Thanaraj TA, Abu-Farha M, Abubaker J, Al-Mulla F. Association of COVID-19 Vaccines ChAdOx1-S and BNT162b2 with Circulating Levels of Coagulation Factors and Antithrombin. Vaccines. 2022; 10(8):1226. https://doi.org/10.3390/vaccines10081226
Chicago/Turabian StyleHasan, Amal, Hossein Arefanian, Arshad Mohamed Channanath, Irina AlKhairi, Preethi Cherian, Sriraman Devarajan, Thangavel Alphonse Thanaraj, Mohamed Abu-Farha, Jehad Abubaker, and Fahd Al-Mulla. 2022. "Association of COVID-19 Vaccines ChAdOx1-S and BNT162b2 with Circulating Levels of Coagulation Factors and Antithrombin" Vaccines 10, no. 8: 1226. https://doi.org/10.3390/vaccines10081226
APA StyleHasan, A., Arefanian, H., Channanath, A. M., AlKhairi, I., Cherian, P., Devarajan, S., Thanaraj, T. A., Abu-Farha, M., Abubaker, J., & Al-Mulla, F. (2022). Association of COVID-19 Vaccines ChAdOx1-S and BNT162b2 with Circulating Levels of Coagulation Factors and Antithrombin. Vaccines, 10(8), 1226. https://doi.org/10.3390/vaccines10081226